Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1856 1
1970 1
1972 1
1977 1
1978 3
1981 2
1983 1
1984 1
1985 1
1986 5
1987 1
1988 4
1989 2
1991 4
1992 3
1993 7
1994 3
1995 5
1996 3
1997 4
1998 6
1999 5
2000 7
2001 8
2002 2
2003 4
2004 3
2005 7
2006 5
2007 11
2008 6
2009 11
2010 7
2011 5
2012 6
2013 12
2014 16
2015 11
2016 8
2017 13
2018 19
2019 10
2020 21
2021 20
2022 22
2023 22
2024 6

Text availability

Article attribute

Article type

Publication date

Search Results

287 results

Results by year

Filters applied: . Clear all
Page 1
Diagnosis of myelin oligodendrocyte glycoprotein antibody-associated disease: International MOGAD Panel proposed criteria.
Banwell B, Bennett JL, Marignier R, Kim HJ, Brilot F, Flanagan EP, Ramanathan S, Waters P, Tenembaum S, Graves JS, Chitnis T, Brandt AU, Hemingway C, Neuteboom R, Pandit L, Reindl M, Saiz A, Sato DK, Rostasy K, Paul F, Pittock SJ, Fujihara K, Palace J. Banwell B, et al. Among authors: bennett jl. Lancet Neurol. 2023 Mar;22(3):268-282. doi: 10.1016/S1474-4422(22)00431-8. Epub 2023 Jan 24. Lancet Neurol. 2023. PMID: 36706773 Review.
These proposed diagnostic criteria require validation but have the potential to improve identification of individuals with MOGAD, which is essential to define long-term clinical outcomes, refine inclusion criteria for clinical trials, and identify predictors of a relapsing …
These proposed diagnostic criteria require validation but have the potential to improve identification of individuals with MOGAD, which is e …
International consensus diagnostic criteria for neuromyelitis optica spectrum disorders.
Wingerchuk DM, Banwell B, Bennett JL, Cabre P, Carroll W, Chitnis T, de Seze J, Fujihara K, Greenberg B, Jacob A, Jarius S, Lana-Peixoto M, Levy M, Simon JH, Tenembaum S, Traboulsee AL, Waters P, Wellik KE, Weinshenker BG; International Panel for NMO Diagnosis. Wingerchuk DM, et al. Among authors: bennett jl. Neurology. 2015 Jul 14;85(2):177-89. doi: 10.1212/WNL.0000000000001729. Epub 2015 Jun 19. Neurology. 2015. PMID: 26092914 Free PMC article.
The International Panel for NMO Diagnosis (IPND) was convened to develop revised diagnostic criteria using systematic literature reviews and electronic surveys to facilitate consensus. The new nomenclature defines the unifying term NMO spectrum disorders (NMOSD), which is …
The International Panel for NMO Diagnosis (IPND) was convened to develop revised diagnostic criteria using systematic literature reviews and …
Steroid-sparing maintenance immunotherapy for MOG-IgG associated disorder.
Chen JJ, Flanagan EP, Bhatti MT, Jitprapaikulsan J, Dubey D, Lopez Chiriboga ASS, Fryer JP, Weinshenker BG, McKeon A, Tillema JM, Lennon VA, Lucchinetti CF, Kunchok A, McClelland CM, Lee MS, Bennett JL, Pelak VS, Van Stavern G, Adesina OO, Eggenberger ER, Acierno MD, Wingerchuk DM, Lam BL, Moss H, Beres S, Gilbert AL, Shah V, Armstrong G, Heidary G, Cestari DM, Stiebel-Kalish H, Pittock SJ. Chen JJ, et al. Among authors: bennett jl. Neurology. 2020 Jul 14;95(2):e111-e120. doi: 10.1212/WNL.0000000000009758. Epub 2020 Jun 17. Neurology. 2020. PMID: 32554760 Free PMC article.
The optimal treatment for reducing relapses is unknown. To help determine the efficacy of long-term immunotherapy in preventing relapse in patients with MOGAD, we conducted a multicenter retrospective study to determine the rate of relapses on various treatments. METHODS: …
The optimal treatment for reducing relapses is unknown. To help determine the efficacy of long-term immunotherapy in preventing relap …
Clinical Trial of Fluid Infusion Rates for Pediatric Diabetic Ketoacidosis.
Kuppermann N, Ghetti S, Schunk JE, Stoner MJ, Rewers A, McManemy JK, Myers SR, Nigrovic LE, Garro A, Brown KM, Quayle KS, Trainor JL, Tzimenatos L, Bennett JE, DePiero AD, Kwok MY, Perry CS 3rd, Olsen CS, Casper TC, Dean JM, Glaser NS; PECARN DKA FLUID Study Group. Kuppermann N, et al. Among authors: bennett je. N Engl J Med. 2018 Jun 14;378(24):2275-2287. doi: 10.1056/NEJMoa1716816. N Engl J Med. 2018. PMID: 29897851 Free PMC article. Clinical Trial.
Secondary outcomes included clinically apparent brain injury during treatment for diabetic ketoacidosis, short-term memory during treatment for diabetic ketoacidosis, and memory and IQ 2 to 6 months after recovery from diabetic ketoacidosis. ...No significant differences a …
Secondary outcomes included clinically apparent brain injury during treatment for diabetic ketoacidosis, short-term memory during tre …
Long-term Efficacy of Satralizumab in AQP4-IgG-Seropositive Neuromyelitis Optica Spectrum Disorder From SAkuraSky and SAkuraStar.
Kleiter I, Traboulsee A, Palace J, Yamamura T, Fujihara K, Saiz A, Javed A, Mayes D, Büdingen HV, Klingelschmitt G, Stokmaier D, Bennett JL. Kleiter I, et al. Among authors: bennett jl. Neurol Neuroimmunol Neuroinflamm. 2022 Dec 8;10(1):e200071. doi: 10.1212/NXI.0000000000200071. Print 2023 Jan. Neurol Neuroimmunol Neuroinflamm. 2022. PMID: 36724181 Free PMC article. Clinical Trial.
BACKGROUND AND OBJECTIVES: Satralizumab, an interleukin 6 receptor inhibitor, reduced the risk of protocol-defined relapse (PDR) vs placebo in 2 independent, double-blind studies in patients with neuromyelitis optica spectrum disorder (NMOSD). We assessed the long-term eff …
BACKGROUND AND OBJECTIVES: Satralizumab, an interleukin 6 receptor inhibitor, reduced the risk of protocol-defined relapse (PDR) vs placebo …
Long-term Effectiveness of Adjuvant Treatment With Catechol-O-Methyltransferase or Monoamine Oxidase B Inhibitors Compared With Dopamine Agonists Among Patients With Parkinson Disease Uncontrolled by Levodopa Therapy: The PD MED Randomized Clinical Trial.
Gray R, Patel S, Ives N, Rick C, Woolley R, Muzerengi S, Gray A, Jenkinson C, McIntosh E, Wheatley K, Williams A, Clarke CE; PD MED Collaborative Group. Gray R, et al. JAMA Neurol. 2022 Feb 1;79(2):131-140. doi: 10.1001/jamaneurol.2021.4736. JAMA Neurol. 2022. PMID: 34962574 Free PMC article. Clinical Trial.
Among these patients, it is uncertain which drug class is more effective as adjuvant therapy. OBJECTIVE: To compare the long-term effects on patient-rated quality of life of adding a dopamine agonist vs a dopamine reuptake inhibitor (DRI), either a monoamine oxidase type B …
Among these patients, it is uncertain which drug class is more effective as adjuvant therapy. OBJECTIVE: To compare the long-term eff …
Association between B-cell depletion and attack risk in neuromyelitis optica spectrum disorder: An exploratory analysis from N-MOmentum, a double-blind, randomised, placebo-controlled, multicentre phase 2/3 trial.
Bennett JL, Aktas O, Rees WA, Smith MA, Gunsior M, Yan L, She D, Cimbora D, Pittock SJ, Weinshenker BG, Paul F, Marignier R, Wingerchuk D, Cutter G, Green A, Hartung HP, Kim HJ, Fujihara K, Levy M, Katz E, Cree BAC; N-MOmentum study investigators. Bennett JL, et al. EBioMedicine. 2022 Dec;86:104321. doi: 10.1016/j.ebiom.2022.104321. Epub 2022 Nov 10. EBioMedicine. 2022. PMID: 36370634 Free PMC article. Clinical Trial.
All participants receiving inebilizumab demonstrated a robust long-term therapeutic response, and participants with 4 cells/muL after the first 6-month dosing interval had persistently deeper B-cell depletion, lower annualised attack rates (estimated rate [95% CI]: 0.034 [ …
All participants receiving inebilizumab demonstrated a robust long-term therapeutic response, and participants with 4 cells/muL after …
Long-term effectiveness of dopamine agonists and monoamine oxidase B inhibitors compared with levodopa as initial treatment for Parkinson's disease (PD MED): a large, open-label, pragmatic randomised trial.
PD Med Collaborative Group; Gray R, Ives N, Rick C, Patel S, Gray A, Jenkinson C, McIntosh E, Wheatley K, Williams A, Clarke CE. PD Med Collaborative Group, et al. Lancet. 2014 Sep 27;384(9949):1196-205. doi: 10.1016/S0140-6736(14)60683-8. Epub 2014 Jun 11. Lancet. 2014. PMID: 24928805 Clinical Trial.
We aimed to establish which of these three classes of drug, as initial treatment, provides the most effective long-term control of symptoms and best quality of life for people with early Parkinson's disease. ...
We aimed to establish which of these three classes of drug, as initial treatment, provides the most effective long-term control of sy …
A Distinctive Adnexal (Usually Paratubal) Neoplasm Often Associated With Peutz-Jeghers Syndrome and Characterized by STK11 Alterations (STK11 Adnexal Tumor): A Report of 22 Cases.
Bennett JA, Young RH, Howitt BE, Croce S, Wanjari P, Zhen C, Da Cruz Paula A, Meserve E, Schoolmeester JK, Westbom-Fremer S, Benzi E, Patil NM, Kooreman L, El-Bahrawy M, Zannoni GF, Krausz T, McCluggage WG, Weigelt B, Ritterhouse LL, Oliva E. Bennett JA, et al. Am J Surg Pathol. 2021 Aug 1;45(8):1061-1074. doi: 10.1097/PAS.0000000000001677. Am J Surg Pathol. 2021. PMID: 33534223 Free PMC article.
Wolffian, sex cord stromal, epithelial, and mesothelial origins were considered. We propose the term STK11 adnexal tumor to describe this novel entity and emphasize the importance of genetic counseling in these patients as a significant number of neoplasms occur in associa …
Wolffian, sex cord stromal, epithelial, and mesothelial origins were considered. We propose the term STK11 adnexal tumor to describe …
Coronary revascularization in patients with HIV.
McCutcheon K, Triantafyllis AS, Van den Eynde J, Oosterlinck W, Vachiat A, Tsabedze N, Zachariah D, Manga P, Bennett J. McCutcheon K, et al. Among authors: bennett j. Trends Cardiovasc Med. 2022 Apr;32(3):163-169. doi: 10.1016/j.tcm.2021.02.006. Epub 2021 Feb 21. Trends Cardiovasc Med. 2022. PMID: 33626383 Review.
PLWH presenting with a ST-segment elevation myocardial infarction are likely to have a high thrombus burden and are at high risk for in-hospital and long-term adverse events. An increasing number of PLWH are presenting with stable coronary artery disease related to atheros …
PLWH presenting with a ST-segment elevation myocardial infarction are likely to have a high thrombus burden and are at high risk for in-hosp …
287 results